OSE Immunotherapeutics announced positive topline results from the TEDOVA Phase 2 trial evaluating Tedopi® with or without pembrolizumab as maintenance treatment in platinum-sensitive recurrent ovarian cancer. The trial showed a significant improvement in progression-free survival (PFS) with the combination of Tedopi® and pembrolizumab compared to best supportive care (4.1 months vs 2.8 months). This is the first positive trial in platinum-sensitive ovarian cancer in years, highlighting Tedopi®'s potential as a vaccine strategy in this difficult-to-treat cancer. Results will be presented at the ASCO 2026 Annual Meeting, with further development planned including Phase 3 trials and combination studies in other cancers.
Mowi ASA announced that its shares will be traded ex-dividend with a dividend amount of NOK 2.30 per share starting from May 22, 2026. This follows the board's decision on May 12, 2026, to distribute a quarterly dividend to shareholders. The ex-divid...
Mowi ASA announced that its shares will be traded ex-dividend at NOK 2.30 per share starting May 22, 2026. This follows the board's decision on May 12, 2026, to distribute a quarterly dividend of NOK 2.30 to shareholders. The company also scheduled i...
Yimutian Inc., a Chinese agricultural digital service company, has formally requested a hearing with Nasdaq's Hering Panel after receiving a delisting notice due to not meeting minimum market value requirements. The hearing request halts any immediat...
Vipshop Holdings exceeded consensus estimates for its Q1 2026 EBIT and EPS by 5% and 2%, respectively. The company is expected to return to positive revenue and earnings growth for the full year 2026, driven by an optimized marketing strategy, expans...
Frustration is growing in the Ethereum community after key contributors, including Dankrad Feist, left the Ethereum Foundation. Feist proposed creating a new organization with at least $1 billion in funding, directly aligned with Ethereum's economic ...
